Pathological characteristics in FOXP1 negative and positive FL cases
| . | BCCA . | GLSG . | ||||||
|---|---|---|---|---|---|---|---|---|
| . | Evaluable . | FOXP1 low, n (%) . | FOXP1 high, n (%) . | P . | Evaluable . | FOXP1 low, n (%) . | FOXP1 high, n (%) . | P . |
| Grade 1-2 | 252 | 91 (85) | 126 (87) | — | — | — | — | |
| Grade 3A | 16 (15) | 19 (12) | .715 | |||||
| BCL2 translocation negative | 221 | 7 (8) | 26 (20) | 322 | 14 (11) | 37 (18) | ||
| BCL2 translocation positive | 86 (92) | 102 (80) | .012 | 106 (89) | 165 (82) | .155 | ||
| BCL6 translocation negative | 232 | 84 (88) | 110 (81) | — | — | — | — | |
| BCL6 translocation positive | 12 (13) | 26 (19) | .210 | |||||
| MYC translocation negative | 197 | 77 (96) | 108 (92) | — | — | — | — | |
| MYC translocation positive | 3 (4) | 9 (8) | .366 | |||||
| CD10 IHC negative | 223 | 7 (7) | 11 (8) | — | — | — | — | |
| CD10 IHC positive | 99 (93) | 134 (92) | .810 | |||||
| BCL6 IHC negative | 252 | 4 (4) | 5 (3) | — | — | — | — | |
| BCL6 IHC positive | 103 (96) | 140 (97) | 1.000 | |||||
| IRF4 IHC negative | 252 | 106 (98) | 127 (88) | 359 | 123 (91) | 174 (78) | ||
| IRF4 IHC positive | 1 (2) | 18 (12) | .002 | 12 (9) | 50 (22) | .001 | ||
| TP53 IHC negative | 252 | 106 (99) | 139 (96) | — | — | — | — | |
| TP53 IHC positive | 1 (1) | 6 (4) | .244 | |||||
| . | BCCA . | GLSG . | ||||||
|---|---|---|---|---|---|---|---|---|
| . | Evaluable . | FOXP1 low, n (%) . | FOXP1 high, n (%) . | P . | Evaluable . | FOXP1 low, n (%) . | FOXP1 high, n (%) . | P . |
| Grade 1-2 | 252 | 91 (85) | 126 (87) | — | — | — | — | |
| Grade 3A | 16 (15) | 19 (12) | .715 | |||||
| BCL2 translocation negative | 221 | 7 (8) | 26 (20) | 322 | 14 (11) | 37 (18) | ||
| BCL2 translocation positive | 86 (92) | 102 (80) | .012 | 106 (89) | 165 (82) | .155 | ||
| BCL6 translocation negative | 232 | 84 (88) | 110 (81) | — | — | — | — | |
| BCL6 translocation positive | 12 (13) | 26 (19) | .210 | |||||
| MYC translocation negative | 197 | 77 (96) | 108 (92) | — | — | — | — | |
| MYC translocation positive | 3 (4) | 9 (8) | .366 | |||||
| CD10 IHC negative | 223 | 7 (7) | 11 (8) | — | — | — | — | |
| CD10 IHC positive | 99 (93) | 134 (92) | .810 | |||||
| BCL6 IHC negative | 252 | 4 (4) | 5 (3) | — | — | — | — | |
| BCL6 IHC positive | 103 (96) | 140 (97) | 1.000 | |||||
| IRF4 IHC negative | 252 | 106 (98) | 127 (88) | 359 | 123 (91) | 174 (78) | ||
| IRF4 IHC positive | 1 (2) | 18 (12) | .002 | 12 (9) | 50 (22) | .001 | ||
| TP53 IHC negative | 252 | 106 (99) | 139 (96) | — | — | — | — | |
| TP53 IHC positive | 1 (1) | 6 (4) | .244 | |||||
Bold values indicate statistical significance.